Labor/HHS appropriations
This article was originally published in The Tan Sheet
Executive Summary
Bill providing NIH funding for fiscal 2002 awaits President Bush's signature following rush by Congress to pass measure before year-end recess. House approved conference report Dec. 19 in 393-30 vote; Senate passed bill 90-7 on Dec. 20. Legislation gives NIH total program level budget of $22.89 bil. for FY 2002, marking a $2.79 bil. (or 14%) increase over fiscal 2001...
You may also be interested in...
Labor/HHS appropriations
Conference report urges HHS secretary "to form a coordinating unit to review" White House CAM Commission report and "implement ways to better coordinate the department's many CAM-related activities." Conferees also urge secretary "to work with FDA and ODS to resolve [ephedra] rulemaking expeditiously." Appropriations bill, passed by Congress before the holiday recess, provides $17 mil. to ODS (up 70% from FY 2001), $104.6 mil. to NCCAM (up 17.3%) (1"The Tan Sheet" Dec. 24, 2001, In Brief). Conference report also calls for publication of dietary supplement GMPs within 15 days of bill's enactment; however, FDA withdrew GMPs proposed rule from OMB Dec. 19...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.